Skip to main content

Neumann Mark's Form 4 filing

Intra-Cellular Therapies, Inc. (ITCI) · filed Feb 22, 2023

Accession no.
0001209191-23-012001
Filed
Feb 22, 2023
Trade date
Feb 18-21, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $183.2K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Neumann MarkCIK 0001756211Officer (EVP, Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 18, 2023Common StockMOption exerciseAcquired+11,139––56,478Direct
Feb 21, 2023Common StockSSaleDisposed−3,140$46.61−$146,355.453,338Direct
Feb 21, 2023Common StockSSaleDisposed−123$47.32−$5,820.3653,215Direct
Feb 21, 2023Common StockSSaleDisposed−635$48.93−$31,070.5552,580Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 18, 2023Common StockMOption exerciseDisposed−11,139$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)